{
  "docId": "019de517-44b3-71b5-8a8d-243b41bb1797",
  "docSlug": "c77cf9536b998c2f906519be4212f807",
  "documentTitle": "GH Research | Investor Presentation Deck | 30 slides",
  "authorId": "gh-research",
  "authorName": "GH Research",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 30,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The pipeline uses a Gantt-chart like visualization to show progress through preclinical and clinical phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/4",
  "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797",
  "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json",
  "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.039,
        "w": 0.149,
        "x": 0.815,
        "y": 0.03
      },
      "kind": "image",
      "text": "GH Research logo",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08f83522-f809-4c36-9541-6bf5a4db3cf9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.57,
        "x": 0.069,
        "y": 0.883
      },
      "kind": "list",
      "text": "*Bipolar II disorder with a current major depressive episode\n5-MeO-DMT, 5-Methoxy-N,N-Dimethyltryptamine; i.v., intravenous; RDBPC, Randomized, Double-Blind, Placebo-Controlled; POC, Proof-of-Concept; HV, Healthy Volunteer",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac386d3b-b100-4c0c-a2ff-9236b51de3cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.17,
        "x": 0.042,
        "y": 0.945
      },
      "kind": "source-note",
      "text": "2023© GH Research PLC",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d37ac569-e9ee-41de-a034-9461d939f034",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.653,
        "w": 0.832,
        "x": 0.069,
        "y": 0.219
      },
      "kind": "table",
      "text": "PROGRAMS, INDICATION, PRECLINICAL, PHASE 1, PHASE 2a, PHASE 2b, PHASE 3, CURRENT STATUS, GH001 Mebufotenin (5-MeO-DMT) for inhalation administration, Treatment-Resistant Depression (TRD), Bipolar II Disorder* (BDII), Postpartum Depression (PPD), GH002 Mebufotenin (5-MeO-DMT) for i.v. administration, Psychiatric or Neurological Disorder, GH003 Mebufotenin (5-MeO-DMT) for nasal administration, Psychiatric or Neurological Disorder, Phase 2b RDBPC trial initiated (GH001-TRD-201), Phase 2a POC trial initiated (GH001-BD-202), Phase 2a POC trial initiated (GH001-PPD-203), Phase 1 HV trial initiated (GH002-HV-105), Pre-clinical development ongoing",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b47a028-5bb7-425d-9af2-151837fdb578",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.22,
        "x": 0.071,
        "y": 0.09
      },
      "kind": "title",
      "text": "Pipeline",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0514d214-2122-4a6b-9662-6c97bb8fd86c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa",
      "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions",
      "position": 1,
      "objective": "Explain why GH001 is a necessary solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}